HCPCS Level II code J9381 denotes an injection of teplizumab-mzwv, 5 mcg. As a HCPCS Level II drug code, it identifies a specific biologic product administered in outpatient settings and billed as a drug line item. Nationally, precise coding for biologics like teplizumab-mzwv matters for claims accuracy, patient access, and payer contracting because it affects reimbursement, utilization tracking, and prior authorization workflows.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context and service settings, payer coverage considerations, common modifiers used with HCPCS drug codes, and guidance on where to locate payer policies and billing guidance. The publication summarizes benchmarks for drug billing and utilization where available and flags typical administrative steps payers expect for biologic drug claims, such as NDC reporting, route and site of service documentation, and applicable prior authorization requirements.

This overview is intended for revenue cycle, pharmacy, and clinical administrative audiences seeking a national perspective on billing and coding practices for teplizumab-mzwv using HCPCS Level II code J9381.